---
title: "D2 Equipoise: when medical knowledge can only advance by experimenting"
shorttitle: "Understanding equipoise"
author: "Vincent J. Carey, stvjc at channing.harvard.edu"
date: "`r format(Sys.time(), '%B %d, %Y')`"
vignette: >
  %\VignetteEngine{knitr::rmarkdown}
  %\VignetteIndexEntry{D2 Equipoise: when medical knowledge can only advance by experimenting}
  %\VignetteEncoding{UTF-8}
output:
  rmarkdown::html_document:
    highlight: pygments
    number_sections: yes
    theme: united
    toc: yes
---

```{r setup,echo=FALSE,results="hide"}
suppressMessages({
 suppressPackageStartupMessages({
  library(YESCDS)
library(tibble)
library(dplyr)
library(plotly)
library(ggplot2)
library(ggbeeswarm)
library(DT)
data(woncan_meta)
data(woncan)
littab = woncan |> select(MSA, `Cancer Sites`, Age.Adjusted.Rate) |> as.data.frame()
  })
 })
```

# Equipoise: individual and clinical

Distinguished in [AMA ethics, 2015](https://journalofethics.ama-assn.org/article/question-clinical-equipoise-and-patients-best-interests/2015-12)

> What is the state of medical knowledge? Why is this trial asking an important question? How does the likelihood of benefiting in study A compare with that of benefiting in study B or with the standard of care? -- attributed to B. Freedman

- Belief in the new treatment

- Belief in the patient's suitability for the new treatment

- Interpretation of new evidence

- Risk that new evidence will "regress"

- Alternative: fully informed patient consent

# Discussion Questions

D.2.1 
